[A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)].
A 59-year-old man was admitted to our hospital with a left renal mass. A tumor was removed by radical nephrectomy and histological examination revealed renal cell carcinoma (pT2 N0 V1a). Two years later, CT scan showed multiple lung metastases. Despite treatment with recombinant IFN-alpha 2b, 5-FU, and MMC, the disease showed slow progression. About three years after the start of combination therapy, cervical lymph node metastasis appeared. Administration of interleukin-2 (IL-2) was attempted. Intravenous IL-2 therapy was started at a low daily dose of 35 x 10(4) JRU, and the daily dose was increased to 140 x 10(4) JRU. Because of side effect, the dose was subsequently decreased to 70 x 10(4) JRU three times per week. After 31 weeks of IL-2 therapy, his multiple lung metastases and cervical lymph node metastasis disappeared. The patient's natural killer cell (NK) activity and Lymphokine activated killer cell (LAK) activity were low before IL-2 therapy, but both NK activity and LAK activity showed a marked increase after IL-2 therapy started. Therefore, the tumor response to IL-2 was suggested to depend on NK activity and LAK activity.
Department of Urology, Nagoya Daini Red Cross Hospital.
Toshinori
T
Nishikimi
Ryo
R
Ishida
Hiroshi
H
Yamada
Keisuke
K
Yokoi
Hiroaki
H
Kobayashi
Kouji
K
Obata
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009333:Neck; D011788:Quality of Life; D011994:Recombinant Proteins; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins